

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 12/01/2018

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	data CTS	AIC	Confezione
ZEJULA	EMEA/H/C/4249	L01XX54	niraparib	TESARO UK LIMITED	14-set-17	16-nov-17	29-dic-17	17-gen-18	045690017	1
Ontruzant	EMEA/H/C/4323	L01XC03	trastuzumab	Samsung Bioepis UK Limited	14-set-17	15-nov-17	29-dic-17	17-gen-18	045778014	1
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780018	1
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780020	2
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780032	3
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780044	4
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780057	5
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780069	6
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780071	7
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780083	8
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780095	9
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780107	10
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780119	11
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780121	12
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780133	13
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780145	14
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780158	15
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780160	16
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780172	17
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780184	18
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780196	19
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780208	20
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780210	21
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780222	22
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780234	23
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780246	24
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780259	25
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780261	26
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780273	27
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780285	28
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780297	29
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780309	30
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780311	31
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780323	32
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780335	33
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780347	34
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780350	35
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780362	36
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780374	37
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780386	38
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780398	39
Imatinib Teva B.V.	EMEA/H/C/4748	L01XE01	imatinib	Teva B.V.	14-set-17	15-nov-17	29-dic-17	17-gen-18	045780400	40
Elebrato Ellipta	EMEA/H/C/4781	Pending	fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline Trading Services Limited	14-set-17	15-nov-17	29-dic-17	17-gen-18	045789017	1
Elebrato Ellipta	EMEA/H/C/4781	Pending	fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline Trading Services Limited	14-set-17	15-nov-17	29-dic-17	17-gen-18	045789029	2
Elebrato Ellipta	EMEA/H/C/4781	Pending	fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline Trading Services Limited	14-set-17	15-nov-17	29-dic-17	17-gen-18	045789031	3
Trelegly Ellipta	EMEA/H/C/4363	Pending	fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline Trading Services Limited	14-set-17	15-nov-17	29-dic-17	17-gen-18	045790019	1
Trelegly Ellipta	EMEA/H/C/4363	Pending	fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline Trading Services Limited	14-set-17	15-nov-17	29-dic-17	17-gen-18	045790021	2
Trelegly Ellipta	EMEA/H/C/4363	Pending	fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline Trading Services Limited	14-set-17	15-nov-17	29-dic-17	17-gen-18	045790033	3
Cyltezo	EMEA/H/C/4319	L04AB04	adalimumab	Boehringer Ingelheim International GmbH	14-set-17	10-nov-17	29-dic-17	17-gen-18	045776010	1

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 12/01/2018

Cyltezo	EMEA/H/C/4319	L04AB04	adalimumab	Boehringer Ingelheim International GmbH	14-set-17	10-nov-17	29-dic-17	17-gen-18	045776022	2
Cyltezo	EMEA/H/C/4319	L04AB04	adalimumab	Boehringer Ingelheim International GmbH	14-set-17	10-nov-17	29-dic-17	17-gen-18	045776034	3
Cyltezo	EMEA/H/C/4319	L04AB04	adalimumab	Boehringer Ingelheim International GmbH	14-set-17	10-nov-17	29-dic-17	17-gen-18	045776046	4
Cyltezo	EMEA/H/C/4319	L04AB04	adalimumab	Boehringer Ingelheim International GmbH	14-set-17	10-nov-17	29-dic-17	17-gen-18	045776059	5
Cyltezo	EMEA/H/C/4319	L04AB04	adalimumab	Boehringer Ingelheim International GmbH	14-set-17	10-nov-17	29-dic-17	17-gen-18	045776061	6
Cyltezo	EMEA/H/C/4319	L04AB04	adalimumab	Boehringer Ingelheim International GmbH	14-set-17	10-nov-17	29-dic-17	17-gen-18	045776073	7
Cyltezo	EMEA/H/C/4319	L04AB04	adalimumab	Boehringer Ingelheim International GmbH	14-set-17	10-nov-17	29-dic-17	17-gen-18	045776085	8
Ritonavir Mylan	EMEA/H/C/4549	J05AE03	ritonavir	Mylan S.A.S	14-set-17	10-nov-17	29-dic-17	17-gen-18	045775018	1
Ritonavir Mylan	EMEA/H/C/4549	J05AE03	ritonavir	Mylan S.A.S	14-set-17	10-nov-17	29-dic-17	17-gen-18	045775020	2
Ritonavir Mylan	EMEA/H/C/4549	J05AE03	ritonavir	Mylan S.A.S	14-set-17	10-nov-17	29-dic-17	17-gen-18	045775032	3
Nyxoid	EMEA/H/C/4325	V03AB15	naloxone	Mundipharma Corporation Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	045777012	1
TOOKAD	EMEA/H/C/4182	L01XD07	padeliporfin	Steba Biotech S.A	14-set-17	10-nov-17	29-dic-17	17-gen-18	045774015	1
TOOKAD	EMEA/H/C/4182	L01XD07	padeliporfin	Steba Biotech S.A	14-set-17	10-nov-17	29-dic-17	17-gen-18	045774027	2
Zubsolv	EMEA/H/C/4407	N07BC51	buprenorphine / naloxone	Mundipharma Corporation Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	045779016	1
Zubsolv	EMEA/H/C/4407	N07BC51	buprenorphine / naloxone	Mundipharma Corporation Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	045779028	2
Zubsolv	EMEA/H/C/4407	N07BC51	buprenorphine / naloxone	Mundipharma Corporation Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	045779030	3
Zubsolv	EMEA/H/C/4407	N07BC51	buprenorphine / naloxone	Mundipharma Corporation Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	045779042	4
Zubsolv	EMEA/H/C/4407	N07BC51	buprenorphine / naloxone	Mundipharma Corporation Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	045779055	5
Zubsolv	EMEA/H/C/4407	N07BC51	buprenorphine / naloxone	Mundipharma Corporation Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	045779067	6
VeraSeal	EMEA/H/C/4446	B02BC	human fibrinogen / human thrombin	Istituto Grifols, S.A.	14-set-17	10-nov-17	29-dic-17	17-gen-18	045788015	1
VeraSeal	EMEA/H/C/4446	B02BC	human fibrinogen / human thrombin	Istituto Grifols, S.A.	14-set-17	10-nov-17	29-dic-17	17-gen-18	045788027	2
VeraSeal	EMEA/H/C/4446	B02BC	human fibrinogen / human thrombin	Istituto Grifols, S.A.	14-set-17	10-nov-17	29-dic-17	17-gen-18	045788039	3
VeraSeal	EMEA/H/C/4446	B02BC	human fibrinogen / human thrombin	Istituto Grifols, S.A.	14-set-17	10-nov-17	29-dic-17	17-gen-18	045788041	4
Miglustat Gen.Orph	EMEA/H/C/4366	A16AX06	Miglustat	Gen.Orph	14-set-17	10-nov-17	29-dic-17	17-gen-18	045773013	1
Tremfya	EMEA/H/C/4271	L04AC	Guselkumab	Janssen-Cilag International NV	14-set-17	10-nov-17	29-dic-17	17-gen-18	045772011	1
Tasigna	EMEA/H/C/798/X/88/G	L01XE08	Nilotinib	Novartis Europharm Limited	14-set-17	15-nov-17	29-dic-17	17-gen-18	038328151	15
Revatio	EMEA/H/C/638/IAIN/76	G04BE03	sildenafil	Pfizer Limited	25-nov-16	10-nov-17	29-dic-17	17-gen-18	036982054	5
ellaOne	EMEA/H/C/1027/X/45	G03AD02	ulipristal acetate	Laboratoire HRA Pharma	14-set-17	10-nov-17	29-dic-17	17-gen-18	039366036	3
Kovaltry	EMEA/H/C/3825/IB/2/G	B02BD02	octocog alfa	Bayer AG	20-lug-16	11-apr-17	30-mag-17	17-gen-18	044726115	11
Kovaltry	EMEA/H/C/3825/IB/2/G	B02BD02	octocog alfa	Bayer AG	20-lug-16	11-apr-17	30-mag-17	17-gen-18	044726127	12
Kovaltry	EMEA/H/C/3825/IB/2/G	B02BD02	octocog alfa	Bayer AG	20-lug-16	11-apr-17	30-mag-17	17-gen-18	044726139	13
Kovaltry	EMEA/H/C/3825/IB/2/G	B02BD02	octocog alfa	Bayer AG	20-lug-16	11-apr-17	30-mag-17	17-gen-18	044726141	14
Kovaltry	EMEA/H/C/3825/IB/2/G	B02BD02	octocog alfa	Bayer AG	20-lug-16	11-apr-17	30-mag-17	17-gen-18	044726154	15
Kovaltry	EMEA/H/C/3825/IB/2/G	B02BD02	octocog alfa	Bayer AG	20-lug-16	11-apr-17	30-mag-17	17-gen-18	044726166	16
Exjade	EMEA/H/C/670/X/54	V03AC03	deferasirox	Novartis Europharm Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	037421207	20
Exjade	EMEA/H/C/670/X/54	V03AC03	deferasirox	Novartis Europharm Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	037421219	21
Exjade	EMEA/H/C/670/X/54	V03AC03	deferasirox	Novartis Europharm Limited	14-set-17	10-nov-17	29-dic-17	17-gen-18	037421221	22

La responsabilità di qualsiasi onere e/o attività che l'Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all'immissione in commercio del medicinale, è totalmente a carico dell'Azienda stessa. L'ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.